No Detail Found!

Anti-cardiolipin antibodies and risk of Coronary heart disease hospital-based case-control study:

Author(s)
Mohsen Janghorbani Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran
Mohammad Garak-Yaraghi Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran
Roya Sherkat Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran
Shiva Izadi Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran
Bita Rafiee-Moghadan Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Data concerning the relation between anticardiolipin (aCL) antibodies and coronary heart disease (CHD) in subjects without evidence of overt autoimmune disease are conflicting. The purpose of the present study was to determine whether the presence of aCL antibodies, carries a risk for CHD in a hospital­based case-control study. Using IgG aCL antibody as a risk factor of CHD, a hospital-based case-control study of CHD was conducted in Isfahan, Iran. We examined the sera of 50 CHD cases, aged 30-84 years [mean (Standard Deviation (SD)] 59.7 (12.8) and 100 hospital based controls aged 25-90 [mean (SD) 58.7 (13.7)]. The controls were non-CHD patients, selected from the same hospital as the cases and matched for gender, marital status and age (±5 years). Samples were tested for IgG-clan antibodies to cardiolipin by enzymelinked immunosorbent assay (ELISA). The prevalence of aCL antibody was 2% [95% confidence interval (CI: 0.05 to 10.7)] for cases and 5% (95% Cl: 1.6 to 11.3) for controls and this differences was not statistically significant [odds ratio (95% CI): 0.4 (0.04 to 3.4)]. The odds ratiofor IgG aCL antibody did not suggest an increase risk. The mean (SD) of IgG aCL antibody level was higher in control subjects than in patients [2.7 (2.0) versus 4.7 (7.6); P=0.07]. In a hospital-based. case-control study, the presence of a high IgG aCL antibody level is not an independent risk factor for CHD.
Publication Details
Page(s) 107-111
DOI DOI not available
Published Journal: Hamdard Medicus, Volume: 48, Issue: 1, Year: 2005

Request the full text from PASTIC

0

Citations

0

Downloads

72

Views